Eiichi Shiba
Ohiraki, 5530007, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Pembrolizumab response in stage IV luminal-type breast cancer with high microsatellite instability: a case report.
Journal: Journal of medical case reports
Published: November 15, 2023
A follow-up study of a randomized controlled study evaluating safety and efficacy of leuprorelin acetate every-3-month depot for 2 versus 3 or more years with tamoxifen for 5 years as adjuvant treatment in premenopausal patients with endocrine-responsive breast cancer.
Journal: Breast cancer (Tokyo, Japan)
Published: July 28, 2020
Different sensitivities of senescent breast cancer cells to immune cell-mediated cytotoxicity.
Journal: Cancer science
Published: April 15, 2019
Comparison of quality of life between 2-year and 3-or-more-year administration of leuprorelin acetate every-3-months depot in combination with tamoxifen as adjuvant endocrine treatment in premenopausal patients with endocrine-responsive breast cancer: a randomized controlled trial.
Journal: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
Published: May 16, 2016
A randomized controlled study evaluating safety and efficacy of leuprorelin acetate every-3-months depot for 2 versus 3 or more years with tamoxifen for 5 years as adjuvant treatment in premenopausal patients with endocrine-responsive breast cancer.
Journal: Breast cancer (Tokyo, Japan)
Published: November 13, 2014
Relationship between intrinsic subtypes and tumor responses to neoadjuvant chemotherapy in patients with locally advanced breast cancer.
Journal: Breast disease
Published: March 20, 2013
Showing 1-8 of 8
Last Updated: 09/26/2026